| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Target: Isotope-Labeled Compounds / Endogenous Metabolite. Myristic acid is a saturated fatty acid that serves as an energy source and is a key component of cell membranes. It is involved in protein acylation (myristoylation), a lipid modification that targets proteins to cellular membranes and regulates protein function.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, myristic acid-d5 is used as a tracer in cell culture studies to monitor fatty acid uptake, metabolism, and incorporation into complex lipids. As an internal standard, no direct biological activity is reported. The unlabeled compound can activate GPR84 (a medium-chain fatty acid receptor) at high concentrations. |
| ln Vivo |
In vivo, the compound is used in metabolic flux studies and tracer experiments to track lipid metabolism pathways after oral or intravenous administration to rodents. It does not exert direct pharmacological activity. The unlabeled compound is involved in energy storage and membrane biogenesis in animals.
|
| Enzyme Assay |
For cell-free assays: plasma, tissue homogenates, or cell lysates are processed by lipid extraction (Folch method), followed by saponification and derivatization to fatty acid methyl esters (FAMEs). The samples are analyzed by GC-MS or LC-MS, and the labeled internal standard enables absolute quantitation of myristic acid by correcting for extraction efficiency and ion suppression.
|
| Cell Assay |
For cell assays: adipocytes, hepatocytes, or myotubes are incubated with media containing myristic acid-d5 (typically 50-200 uM) complexed to fatty acid-free BSA for 2-24 hours. Lipid extracts are analyzed by LC-MS to quantify the incorporation of the labeled fatty acid into triglycerides, phospholipids, and cholesteryl esters.
|
| Animal Protocol |
For animal studies: mice are administered myristic acid-d5 (oral gavage or IP injection, typically 10-50 mg/kg) for metabolic tracer studies. Serial blood samples are collected, and tissues (liver, adipose, muscle) are harvested post-mortem for analysis of incorporated label into various lipid classes by GC-MS or LC-MS.
|
| ADME/Pharmacokinetics |
PK properties of myristic acid: rapid absorption from the gastrointestinal tract, with peak plasma concentrations occurring 1-2 hours after oral administration. It is transported in the blood via albumin and lipoproteins, taken up by tissues, and metabolized by beta-oxidation in mitochondria. The half-life is short (minutes to hours). The deuterated standard does not alter PK.
|
| Toxicity/Toxicokinetics |
No toxicity is associated with this compound at tracer or internal standard levels. Myristic acid is a dietary fatty acid and is generally safe at normal intake levels. At very high doses, it may contribute to elevated LDL cholesterol levels. The deuterated standard is for research use only and is non-hazardous for transport.
|
| References | |
| Additional Infomation |
Myristic acid-d5 is a research standard, not a drug. It is not FDA-approved for clinical use. It is used extensively in metabolic research, lipidomics, and as a quality control standard in food and cosmetic industries. Myristic acid is a common ingredient in soaps and cosmetics due to its cleansing properties. The labeled compound is used to study fatty acid transport and beta-oxidation disorders.
|
| Molecular Formula |
C14H28O2
|
|---|---|
| Molecular Weight |
228.37092
|
| Exact Mass |
233.24
|
| CAS # |
327077-03-2
|
| Related CAS # |
Myristic acid;544-63-8
|
| PubChem CID |
71309229
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
250ºC/100 mmHg(lit.)
|
| Melting Point |
52-54ºC(lit.)
|
| LogP |
4.772
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
16
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])CCCCCCCCCCCC(=O)O
|
| InChi Key |
TUNFSRHWOTWDNC-ZBJDZAJPSA-N
|
| InChi Code |
InChI=1S/C14H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H,15,16)/i1D3,2D2
|
| Chemical Name |
13,13,14,14,14-pentadeuteriotetradecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3789 mL | 21.8943 mL | 43.7886 mL | |
| 5 mM | 0.8758 mL | 4.3789 mL | 8.7577 mL | |
| 10 mM | 0.4379 mL | 2.1894 mL | 4.3789 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
